These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 12767664)

  • 1. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.
    Crilley JG; Boehm EA; Blair E; Rajagopalan B; Blamire AM; Styles P; McKenna WJ; Ostman-Smith I; Clarke K; Watkins H
    J Am Coll Cardiol; 2003 May; 41(10):1776-82. PubMed ID: 12767664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy.
    Revera M; van der Merwe L; Heradien M; Goosen A; Corfield VA; Brink PA; Moolman-Smook JC
    Cardiovasc Res; 2008 Mar; 77(4):687-94. PubMed ID: 18029407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.
    Sequeira V; Wijnker PJ; Nijenkamp LL; Kuster DW; Najafi A; Witjas-Paalberends ER; Regan JA; Boontje N; Ten Cate FJ; Germans T; Carrier L; Sadayappan S; van Slegtenhorst MA; Zaremba R; Foster DB; Murphy AM; Poggesi C; Dos Remedios C; Stienen GJ; Ho CY; Michels M; van der Velden J
    Circ Res; 2013 May; 112(11):1491-505. PubMed ID: 23508784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy.
    Luedde M; Flögel U; Knorr M; Grundt C; Hippe HJ; Brors B; Frank D; Haselmann U; Antony C; Voelkers M; Schrader J; Most P; Lemmer B; Katus HA; Frey N
    J Mol Med (Berl); 2009 Apr; 87(4):411-22. PubMed ID: 19189074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy.
    Vakrou S; Liu Y; Zhu L; Greenland GV; Simsek B; Hebl VB; Guan Y; Woldemichael K; Talbot CC; Aon MA; Fukunaga R; Abraham MR
    Sci Rep; 2021 Jun; 11(1):13163. PubMed ID: 34162896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echocardiographic Strain Abnormalities Precede Left Ventricular Hypertrophy Development in Hypertrophic Cardiomyopathy Mutation Carriers.
    Canciello G; Lombardi R; Borrelli F; Ordine L; Chen SN; Santoro C; Frisso G; di Napoli S; Polizzi R; Cristiano S; Esposito G; Losi MA
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of R403WMYH7 and R92WTNNT2 HCM families: mutations determine left ventricular dimensions but not wall thickness during disease progression.
    Revera M; Van der Merwe L; Heradien M; Goosen A; Corfield VA; Brink PA; Moolman-Smook JC
    Cardiovasc J Afr; 2007; 18(3):146-53. PubMed ID: 17612745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction.
    Dass S; Cochlin LE; Suttie JJ; Holloway CJ; Rider OJ; Carden L; Tyler DJ; Karamitsos TD; Clarke K; Neubauer S; Watkins H
    Eur Heart J; 2015 Jun; 36(24):1547-54. PubMed ID: 25990345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in cardiac tissue characterization in carriers with gene mutations associated with hypertrophic cardiomyopathy.
    Kaneda T; Shimizu M; Ino H; Yamaguchi M; Terai H; Fujino N; Nagata M; Sakata K; Mabuchi H
    Int J Cardiol; 2005 Sep; 104(2):170-5. PubMed ID: 16168810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.
    Sedaghat-Hamedani F; Kayvanpour E; Tugrul OF; Lai A; Amr A; Haas J; Proctor T; Ehlermann P; Jensen K; Katus HA; Meder B
    Clin Res Cardiol; 2018 Jan; 107(1):30-41. PubMed ID: 28840316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging.
    Esposito A; De Cobelli F; Perseghin G; Pieroni M; Belloni E; Mellone R; Canu T; Gentinetta F; Scifo P; Chimenti C; Frustaci A; Luzi L; Maseri A; Maschio AD
    Heart; 2009 Mar; 95(3):228-33. PubMed ID: 18708417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring inorganic phosphate and intracellular pH in the healthy and hypertrophic cardiomyopathy hearts by in vivo 7T
    Valkovič L; Clarke WT; Schmid AI; Raman B; Ellis J; Watkins H; Robson MD; Neubauer S; Rodgers CT
    J Cardiovasc Magn Reson; 2019 Mar; 21(1):19. PubMed ID: 30871562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.
    Ashrafian H; Redwood C; Blair E; Watkins H
    Trends Genet; 2003 May; 19(5):263-8. PubMed ID: 12711218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.
    Mori AA; Castro LR; Bortolin RH; Bastos GM; Oliveira VF; Ferreira GM; Hirata TDC; Fajardo CM; Sampaio MF; Moreira DAR; Pachón-Mateos JC; Correia EB; Sousa AGMR; Brión M; Carracedo A; Hirata RDC; Hirata MH
    Forensic Sci Int Genet; 2021 May; 52():102478. PubMed ID: 33588347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
    Toepfer CN; Garfinkel AC; Venturini G; Wakimoto H; Repetti G; Alamo L; Sharma A; Agarwal R; Ewoldt JK; Cloonan P; Letendre J; Lun M; Olivotto I; Colan S; Ashley E; Jacoby D; Michels M; Redwood CS; Watkins HC; Day SM; Staples JF; Padrón R; Chopra A; Ho CY; Chen CS; Pereira AC; Seidman JG; Seidman CE
    Circulation; 2020 Mar; 141(10):828-842. PubMed ID: 31983222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in cardiac energetics between patients with familial and nonfamilial hypertrophic cardiomyopathy.
    Jung WI; Hoess T; Bunse M; Widmaier S; Sieverding L; Breuer J; Apitz J; Schmidt O; van Erckelens F; Dietze GJ; Lutz O
    Circulation; 2000 Mar; 101(12):E121. PubMed ID: 10736302
    [No Abstract]   [Full Text] [Related]  

  • 17. Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?
    Santambrogio GM; Maloberti A; Vallerio P; Peritore A; Spanò F; Occhi L; Musca F; Belli O; De Chiara B; Casadei F; Facchetti R; Turazza F; Manfredini E; Giannattasio C; Moreo A
    Int J Cardiovasc Imaging; 2019 Dec; 35(12):2167-2175. PubMed ID: 31321652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes.
    Poutanen T; Tikanoja T; Jääskeläinen P; Jokinen E; Silvast A; Laakso M; Kuusisto J
    Am Heart J; 2006 Mar; 151(3):725.e1-725.e9. PubMed ID: 16504640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of mutations in symptomatic patients with hypertrophic cardiomyopathy in Taiwan.
    Chiou KR; Chu CT; Charng MJ
    J Cardiol; 2015 Mar; 65(3):250-6. PubMed ID: 25086479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic MYH7, MYBPC3, TPM1, TNNT2 and TNNI3 mutations in sporadic hypertrophic cardiomyopathy.
    Núñez L; Gimeno-Blanes JR; Rodríguez-García MI; Monserrat L; Zorio E; Coats C; McGregor CG; Hernandez del Rincón JP; Castro-Beiras A; Hermida-Prieto M
    Circ J; 2013; 77(9):2358-65. PubMed ID: 23782526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.